Cargando…

A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis

BACKGROUND: Randomised controlled trials are becoming increasingly costly and time-consuming. In 2011, Royston and colleagues proposed a particular class of multi-arm multi-stage (MAMS) designs intended to speed up the evaluation of new treatments in phase II and III clinical trials. Their design, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bratton, Daniel J, Phillips, Patrick PJ, Parmar, Mahesh KB
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840569/ https://www.ncbi.nlm.nih.gov/pubmed/24229079 http://dx.doi.org/10.1186/1471-2288-13-139

Ejemplares similares

A multi-arm multi-stage design for binary outcomes and application to tuberculosis
por: Bratton, Daniel, et al.
Publicado: (2013)

Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes
por: Bratton, Daniel J., et al.
Publicado: (2016)

Treatment selection in multi-arm multi-stage designs: With application to a postpartum haemorrhage trial
por: Choodari-Oskooei, Babak, et al.
Publicado: (2023)

Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome
por: Choodari-Oskooei, Babak, et al.
Publicado: (2013)

Assessing the impact of efficacy stopping rules on the error rates under the multi-arm multi-stage framework
por: Blenkinsop, Alexandra, et al.
Publicado: (2019)

Flexible trial design in practice – dropping and adding arms in STAMPEDE: a multi-arm multi-stage randomised controlled trial
por: Sydes, Matthew R, et al.
Publicado: (2011)

Modifying the multi-arm multi-stage (MAMS) design for use in a phase II tuberculosis trial in sub-Saharan Africa with a time-to-event primary outcome
por: Phillips, Patrick, et al.
Publicado: (2013)

The need for a cultural shift from two-arm to multi-arm RCTS
por: Sydes, Matthew R, et al.
Publicado: (2013)

Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial
por: Sydes, Matthew R, et al.
Publicado: (2009)

Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson’s Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer
por: Zeissler, Marie-Louise, et al.
Publicado: (2020)

Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial
por: Sydes, Matthew R, et al.
Publicado: (2012)

Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings
por: Noor, Nurulamin M., et al.
Publicado: (2020)

Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome
por: Choodari-Oskooei, Babak, et al.
Publicado: (2013)

How do multi-stage, multi-arm trials compare to the traditional two-arm parallel group design – a reanalysis of 4 trials
por: Barthel, FM-S, et al.
Publicado: (2009)

Optimal design for multi-arm multi-stage clinical trials
por: Wason, James MS, et al.
Publicado: (2011)

An order restricted multi‐arm multi‐stage clinical trial design
por: Serra, Alessandra, et al.
Publicado: (2022)

Adding new experimental arms to randomised clinical trials: Impact on error rates
por: Choodari-Oskooei, Babak, et al.
Publicado: (2020)

Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform
por: Gilson, C., et al.
Publicado: (2017)

Rethinking non-inferiority: a practical trial design for optimising treatment duration
por: Quartagno, Matteo, et al.
Publicado: (2018)

An optimised multi-arm multi-stage clinical trial design for unknown variance
por: Grayling, Michael J., et al.
Publicado: (2018)

A multi-stage drop-the-losers design for multi-arm clinical trials
por: Wason, James, et al.
Publicado: (2016)

Uptake of the multi-arm multi-stage (MAMS) adaptive platform approach: a trial-registry review of late-phase randomised clinical trials
por: Noor, Nurulamin M, et al.
Publicado: (2022)

Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson’s disease
por: Foltynie, Tom, et al.
Publicado: (2023)

Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome
por: Royston, Patrick, et al.
Publicado: (2013)

Factorial versus multi‐arm multi‐stage designs for clinical trials with multiple treatments
por: Jaki, Thomas, et al.
Publicado: (2016)

Bayesian adaptive decision-theoretic designs for multi-arm multi-stage clinical trials
por: Bassi, Andrea, et al.
Publicado: (2020)

Some recommendations for multi-arm multi-stage trials
por: Wason, James, et al.
Publicado: (2012)

Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis
por: Li, Vivien, et al.
Publicado: (2022)

A comparison of bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials
por: Wason, James, et al.
Publicado: (2013)

Systematic review of available software for multi-arm multi-stage and platform clinical trial design
por: Meyer, Elias Laurin, et al.
Publicado: (2021)

Treatment selection in multi-arm, multi-stage clinical trials
por: Jaki, Thomas, et al.
Publicado: (2013)

An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect
por: Royston, Patrick, et al.
Publicado: (2014)

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
por: Boeree, Martin J, et al.
Publicado: (2017)

A web application for the design of multi-arm clinical trials
por: Grayling, Michael J., et al.
Publicado: (2020)

Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)
por: Murray, Daniel D., et al.
Publicado: (2021)

Designing multi‐arm multi‐stage clinical trials using a risk–benefit criterion for treatment selection
por: Jaki, Thomas, et al.
Publicado: (2015)

Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated
por: Royston, Patrick, et al.
Publicado: (2016)

Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit
por: Royston, Patrick, et al.
Publicado: (2011)

artbin: Extended sample size for randomized trials with binary outcomes
por: Marley-Zagar, Ella, et al.
Publicado: (2023)

A case for conducting business-to-business experiments with multi-arm multi-stage adaptive designs
por: Legare, Jonathan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dplms8l2k9nphc5he8n3n1322u